Waters Stock News

Waters Corporation (NYSE:WAT ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 9:30 AM EDT Company Participants Udit Batra - President, CEO & Director Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst Let's start. Thanks, everybody, for sticking with us.

MILFORD, Mass. , Aug. 26, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.

Waters Corporation (NYSE:WAT ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Amol Chaubal - Senior VP & CFO Caspar Tudor - Head of Investor Relations Udit Batra - President, CEO & Director Conference Call Participants Catherine Walden Ramsey Schulte - Robert W. Baird & Co. Incorporated, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Jack...

Waters (WAT) Q2 Revenue Jumps 9%

Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currency GAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customers Recurring...

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Waters Corporation (NYSE: WAT) and Becton, Dickinson and Company's (NYSE: BDX) Biosciences & Diagnostic Solutions business. Upon completion of the proposed transaction, existing Waters shareholde...

Major U.S. equities indexes were little changed at midday Monday, as investors weighed the possible impact of the latest tariff announcements from President Trump.

Waters Corp (NYSE:WAT) shares fell more than 12% after it announced a business combination deal with BD Biosciences & Diagnostic Solutions (NYSE:BDX), forming a new life sciences and diagnostics leader focused on high-volume, regulated testing markets. The transaction, structured as a Reverse Morris Trust and valued at approximately $17.5 billion, is expected to significantly expand Waters' mar...